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BACKGROUND
We previously reported that there was no significant difference at 30 days or at 1 year 
in the rate of the composite outcome of death, stroke, myocardial infarction, or 
renal failure between patients who underwent coronary-artery bypass grafting 
(CABG) performed with a beating-heart technique (off-pump) and those who under-
went CABG performed with cardiopulmonary bypass (on-pump). We now report 
the results at 5 years (the end of the trial).
METHODS
A total of 4752 patients (from 19 countries) who had coronary artery disease were 
randomly assigned to undergo off-pump or on-pump CABG. For this report, we 
analyzed a composite outcome of death, stroke, myocardial infarction, renal failure, 
or repeat coronary revascularization (either CABG or percutaneous coronary inter-
vention). The mean follow-up period was 4.8 years.
RESULTS
There were no significant differences between the off-pump group and the on-
pump group in the rate of the composite outcome (23.1% and 23.6%, respectively; 
hazard ratio with off-pump CABG, 0.98; 95% confidence interval [CI], 0.87 to 1.10; 
P = 0.72) or in the rates of the components of the outcome, including repeat coro-
nary revascularization, which was performed in 2.8% of the patients in the off-
pump group and in 2.3% of the patients in the on-pump group (hazard ratio, 1.21; 
95% CI, 0.85 to 1.73; P = 0.29). The secondary outcome for the overall period of the 
trial — the mean cost in U.S. dollars per patient — also did not differ signifi-
cantly between the off-pump group and the on-pump group ($15,107 and $14,992, 
respectively; between-group difference, $115; 95% CI, −$697 to $927). There were 
no significant between-group differences in quality-of-life measures.
CONCLUSIONS
In our trial, the rate of the composite outcome of death, stroke, myocardial infarc-
tion, renal failure, or repeat revascularization at 5 years of follow-up was similar 
among patients who underwent off-pump CABG and those who underwent on-
pump CABG. (Funded by the Canadian Institutes of Health Research; CORONARY 
ClinicalTrials.gov number, NCT00463294.)
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Coronary-artery bypass grafting (CABG) reduces the risk of death in pa-tients with extensive coronary artery dis-
ease.1 CABG is usually performed with the use 
of a cardiopulmonary bypass (on-pump CABG). 
With this approach, perioperative mortality is 
approximately 2%, with an additional 5 to 9% 
of patients having myocardial infarction, stroke, or 
renal failure requiring dialysis. The technique of 
performing CABG on a beating heart (off-pump 
CABG) was developed to decrease the risk of peri-
operative complications and to improve long-term 
outcomes; some complications, both periopera-
tive and long term, may be related to the use of 
cardiopulmonary bypass and to cross-clamping 
of the aorta in association with the on-pump 
CABG procedure.
Several small trials have compared off-pump 
CABG and on-pump CABG.2-6 Larger trials have 
also been performed, the largest of which are the 
CABG Off or On Pump Revascularization Study 
(CORONARY) (involving 4752 patients), the Ran-
domized On/Off Bypass (ROOBY) trial (involving 
2203 patients from the Veterans Affairs medical 
system),7,8 the Danish On-pump versus Off-pump 
Randomization Study (DOORS) (involving 900 
patients from Denmark),9,10 and the German Off-
Pump Coronary Artery Bypass Grafting in Elderly 
Patients (GOPCABE) trial (involving 2539 patients 
from Germany).11 None of these previous trials 
have reported long-term outcomes.
To evaluate the long-term effects of off-pump 
versus on-pump CABG, we have now analyzed the 
5-year follow-up data from CORONARY, which 
was conducted in 19 countries. Previously, we 
reported the 30-day12 and 1-year13 outcomes of 
the trial. At 1 year, the first coprimary outcome 
(a composite of death, myocardial infarction, 
stroke, or new renal failure requiring dialysis) 
had occurred in similar numbers of patients in 
each group, but there was a trend toward more 
frequent repeat revascularizations (percutaneous 
coronary intervention [PCI] or CABG) in associa-
tion with off-pump surgery (33 patients [1.4%] 
in the off-pump group vs. 20 patients [0.8%] in 
the on-pump group; hazard ratio, 1.66; 95% 
confidence interval [CI], 0.95 to 2.89; P = 0.07).
Me thods
Trial Design
CORONARY was a randomized, controlled trial 
with blinded adjudication of outcomes, in which 
off-pump CABG and on-pump CABG were com-
pared in patients who were undergoing isolated 
CABG. The primary hypothesis was that off-
pump CABG would be associated with fewer 
major clinical events in the short term (30 days) 
than on-pump CABG and that the benefits of 
off-pump CABG would be maintained in the long 
term (5 years). We have previously published the 
trial design14 and the results at 30 days12 and at 
1 year.13
The trial was designed by the authors and 
approved by national regulatory authorities and 
the ethics committee at each participating center. 
All funding was provided by the Canadian Insti-
tutes of Health Research. The data were gathered 
and analyzed by the Population Health Research 
Institute (McMaster University, Hamilton, Ontario, 
Canada). The authors vouch for the accuracy and 
completeness of the data and all analyses and for 
the fidelity of the trial to the protocol, which 
is available with the full text of this article at 
NEJM.org.
Patients
Patients who were scheduled to undergo CABG 
were eligible to participate in the trial if they 
required isolated CABG with median sternotomy, 
provided written informed consent, and had one 
or more of the following risk factors: an age of 
70 years or more, peripheral arterial disease, 
cerebrovascular disease or carotid stenosis of 
70% or more of the luminal diameter, or renal 
insufficiency. Patients 60 to 69 years of age were 
eligible if they had at least one of the following 
risk factors (and patients 55 to 59 years of age 
were eligible if they had at least two): diabetes 
requiring treatment with an oral hypoglycemic 
agent or insulin, the need for urgent revascular-
ization after an acute coronary syndrome, a left 
ventricular ejection fraction of less than 35%, or a 
history of smoking within 1 year before random-
ization.
Qualification of Surgeons
To ensure that the surgeons were skilled in the 
technique assigned, we used the approach of an 
expertise-based, randomized, controlled trial.15 
Each procedure was performed by a surgeon who 
had expertise in the specific type of surgery that 
the patient was assigned to undergo. Expertise 
was defined as more than 2 years of experience 
after residency training and completion of more 
than 100 cases of the specific technique (either 
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on-pump or off-pump CABG). Surgeons who met 
these criteria for each type of procedure sepa-
rately were considered to have expertise in both 
techniques and were allowed to perform both 
types of CABG during the trial. Trainees were not 
allowed to be the primary surgeon.
Follow-up and Trial Outcomes
Study personnel conducted in-person or telephone 
follow-up with patients or their next of kin (if pa-
tients were not available) at 30 days and at 1 year 
after the procedure and on a yearly basis until 
the end of the trial. If a patient indicated that 
any outcome event had occurred, the patient’s 
physician was contacted to obtain source docu-
ments regarding the event.
The first coprimary outcome was a composite 
of death, nonfatal stroke, nonfatal myocardial 
infarction, or nonfatal new renal failure requir-
ing dialysis at 30 days after randomization. In 
addition to being used to report results at 30 
days,12 this outcome was also assessed at 1 year.13
The second coprimary outcome was a com-
posite of death, nonfatal stroke, nonfatal myo-
cardial infarction, nonfatal new renal failure 
requiring dialysis, or repeat coronary revascu-
larization (PCI or CABG) at the end of the trial 
(a mean of 4.8 years after randomization). We 
now report the results for the second coprimary 
outcome. All deaths in the first 30 days were 
considered to be cardiovascular deaths. All re-
ported components of the first and second copri-
mary outcomes, as well as recurrent angina, 
were reviewed by an adjudication committee, the 
members of which were unaware of the treat-
ment assignments. The outcomes as adjudicated 
by this committee were used in the statistical 
analyses.
Quality of life was assessed with the use of the 
European Quality of Life–5 Dimensions question-
naire (EQ-5D) and the EQ-5D visual-analogue 
scale. The EQ-5D assesses five dimensions of 
quality of life; the total score ranges from 0 to 1, 
with higher scores indicating better quality-of-
life status. The EQ-5D visual-analogue scale as-
sesses the respondent’s self-rated health on a 
vertical visual-analogue scale. The total score 
ranges from 0 to 100%, with higher scores indi-
cating better health status.
In addition to the quality-of-life assessments, 
neurocognitive tests were performed before the 
CABG procedure and at discharge, 30 days, and 
1 year; the details of the tests and their results 
have been described previously.13 The quality-of-
life and neurocognitive tests were optional for 
both the patients and the investigators at the 
study sites. Neurocognitive testing was not per-
formed at the 5-year follow-up, and therefore an 
assessment of neurocognitive status is not in-
cluded in this report.
Economic Analysis
At the end of the trial, we conducted an eco-
nomic analysis to evaluate the secondary out-
come: the cost associated with each type of 
CABG. We hypothesized in the trial protocol 
that the use of off-pump CABG would be either 
cost-neutral or cost-saving as compared with on-
pump CABG. We reported the results at 1 year.16 
We have followed the same approach in this re-
port for the results at the end of the trial, with 
the exception that costs have been adjusted for 
inflation and we applied an annual discounting 
of 3% because the trial spanned many years. All 
figures are in U.S. currency for 2016.
Statistical Analysis
All analyses were conducted according to the 
intention-to-treat principle. We used a time-to-
event analysis with a Cox regression to report 
the long-term outcomes, after testing the as-
sumption of proportional hazards. The time to 
the first occurrence of any one of the compo-
nents of the primary outcome was described with 
the use of Kaplan–Meier survival curves, and the 
comparisons between the two treatment groups 
were performed with a log-rank test. The treat-
ment effect is expressed as the hazard ratio with 
95% confidence intervals, which was derived from 
the Cox proportional-hazards model for the sec-
ond coprimary outcome at 5 years. The compari-
son between the two operative techniques was 
assessed in prespecified subgroups defined by 
diabetes status, cerebrovascular disease status, 
left ventricular function, number of diseased 
vessels, sex, age, body-mass index, region, and 
European System for Cardiac Operative Risk 
Evaluation (EuroSCORE) grade, and tests for 
interaction were performed with the use of a Cox 
proportional-hazards model. We also undertook 
landmark analyses to assess these outcomes 
between 1 year and 5 years, excluding data from 
patients who had had the outcome evaluated in 
the first year or who had no follow-up data past 
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1 year. To analyze the quality-of-life data at each 
follow-up point (i.e., hospital discharge, 30 days, 
1 year, and 5 years), we calculated the changes in 
assessment scores from baseline to the follow-
up point for each patient, limiting the analysis 
to patients for whom data were available both at 
baseline and at the follow-up point being ana-
lyzed. The mean value for the change in score 
was then calculated within each group,17 and 
these means were compared between the two 
groups.
R esult s
Patients
From November 2006 through October 2011, a 
total of 4752 patients were enrolled at 79 hospi-
tals in 19 countries on four continents and were 
randomly assigned to undergo either off-pump 
CABG (2375 patients) or on-pump CABG (2377 
patients). The baseline characteristics of the pa-
tients have been reported previously.12 At the end 
of the trial, follow-up data were available for 
98.8% of the patients (see the Supplementary 
Appendix, available at NEJM.org).
Second Coprimary Outcome
At a mean of 4.8 years after randomization, a 
second coprimary outcome event had occurred 
in 548 patients (23.1%) in the off-pump group 
and in 560 patients (23.6%) in the on-pump 
group (hazard ratio with off-pump CABG, 0.98; 
95% CI, 0.87 to 1.10; P = 0.72) (Fig. 1 and Table 1). 
There were no significant between-group differ-
ences in the rates of the individual components 
of this composite outcome, including the rates 
of repeat revascularization (PCI or CABG), which 
was performed in 66 patients (2.8%) in the off-
pump group and in 55 patients (2.3%) in the 
on-pump group (hazard ratio, 1.21; 95% CI, 0.85 
to 1.73; P = 0.29). In each treatment group, the 
rate of PCI performed because of graft failure 
was similar to that of PCI performed because of 
new lesions (Table S1 in the Supplementary Ap-
pendix).
Secondary Outcome
During the overall period of the trial, there was 
no significant between-group difference in the 
secondary outcome, mean cost per patient 
($15,107 in the off-pump group and $14,992 in 
Figure 1. Kaplan–Meier Curves for the Second Coprimary Outcome at 5 Years.
The second coprimary outcome was a composite of death, nonfatal stroke, nonfatal myocardial infarction, nonfatal new 
renal failure requiring dialysis, or repeat coronary revascularization (percutaneous coronary intervention or coronary‑
artery bypass grafting [CABG]). The inset shows the same data on an enlarged y axis.
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the on-pump group; difference, $115; 95% CI, 
−$697 to $927). There were no significant differ-
ences between the two groups at any point dur-
ing the trial or in any of the categories of costs 
(Table 2). The between-group difference in dis-
counted costs was also not significant (differ-
ence, $96; 95% CI, −$607 to $799).
Quality-of-Life Outcomes
A total of 2845 patients initially agreed to pro-
vide data for the substudy of quality of life. 
There was a small decline in quality of life, as 
measured with the EQ-5D and the EQ-5D visual-
analogue scale, in both groups at the time of 
discharge (Table 3), but this was followed by a 
sharp increase in quality of life as perceived by 
patients in both groups at 30 days, and this 
higher quality of life was sustained to the end of 
the trial. There was no significant difference 
between the two groups in quality-of-life scores 
at any time point. Very similar results were found 
for the 1531 patients who provided data at all 
follow-up points (Table S2 in the Supplementary 
Appendix).
Nonprespecified Outcomes
The rate of repeat coronary angiography was 
similar in the two groups (5.3% in the off-pump 
group and 4.8% in the on-pump group; hazard 
ratio, 1.11; 95% CI, 0.86 to 1.43; P = 0.43) (Ta-
ble 1). In the majority of cases, angiography was 
performed because of ischemic symptoms or 
suspected myocardial infarction (Table S3 in the 
Supplementary Appendix). The rate of recurrent 
angina was also similar in the two groups (1.7% 
in the off-pump group and 1.6% in the on-pump 
group; hazard ratio, 1.05; 95% CI, 0.68 to 1.63; 
P = 0.81), as was the rate of the primary outcome 
among patients who underwent the assigned pro-
cedure (i.e., without crossing over to the other 
procedure) (22.7% in the off-pump group and 
22.9% in the on-pump group; hazard ratio, 0.99; 
95% CI, 0.87 to 1.12; P = 0.86) (Table 1).
In the landmark analysis of the data between 
1 year and 4.8 years, the rate of the primary 
outcome was found to be similar in the two 
groups (11.3% and 11.5%; hazard ratio, 0.98; 
95% CI, 0.82 to 1.18; P = 0.86) (Table S4 in the 
Supplementary Appendix). Landmark analyses 
Outcome
Off-Pump Group 
(N = 2375)
On-Pump Group 
(N = 2377)
Hazard Ratio 
(95% CI) P Value
Second coprimary outcome — no. (%)* 548 (23.1) 560 (23.6) 0.98 (0.87–1.10) 0.72
Death 346 (14.6) 322 (13.5) 1.08 (0.93–1.26) 0.30
Myocardial infarction 178 (7.5) 194 (8.2) 0.92 (0.75–1.13) 0.41
Stroke 55 (2.3) 66 (2.8) 0.83 (0.58–1.19) 0.32
New renal failure requiring dialysis 40 (1.7) 45 (1.9) 0.89 (0.58–1.37) 0.60
Repeat revascularization† 66 (2.8) 55 (2.3) 1.21 (0.85–1.73) 0.29
PCI 59 (2.5) 52 (2.2) 1.15 (0.79–1.66) 0.48
CABG 9 (0.4) 4 (0.2) 2.27 (0.70–7.38) 0.17
Nonprespecified outcomes — no. (%)
Cardiovascular death‡ 237 (10.0) 230 (9.7) 1.04 (0.87–1.24) 0.69
Repeat coronary angiography 125 (5.3) 114 (4.8) 1.11 (0.86–1.43) 0.43
Recurrent angina 41 (1.7) 39 (1.6) 1.05 (0.68–1.63) 0.81
Primary outcome in per‑protocol population 
— no./total no. (%)§
487/2148 (22.7) 499/2182 (22.9) 0.99 (0.87–1.12) 0.86
*  The second coprimary outcome was a composite of death, nonfatal stroke, nonfatal myocardial infarction, new renal 
failure requiring dialysis, and repeat revascularization (percutaneous coronary intervention [PCI] or coronary‑artery by‑
pass grafting [CABG]).
†  Some patients had CABG and a PCI.
‡  All deaths in the first 30 days were considered to be cardiovascular deaths.
§  The per‑protocol population included patients who underwent the randomly assigned procedure (i.e., without crossing 
over to the other procedure).
Table 1. Outcomes at 5 Years.
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also showed that the rates of repeat revascular-
ization (PCI or CABG) were similar in the two 
groups (1.5% in both treatment groups; hazard 
ratio, 1.01; 95% CI, 0.61 to 1.65; P = 0.98), as 
were the rates of repeat coronary angiography 
(3.7% in both treatment groups; hazard ratio, 
1.00; 95% CI, 0.73 to 1.38; P = 0.98) and recur-
rent angina (1.0% in the off-pump group and 
0.9% in the on-pump group; hazard ratio, 1.16; 
95% CI, 0.62 to 2.19; P = 0.64).
Subgroup Analysis
To test the consistency and validity of our re-
sults, we examined the treatment effects in vari-
ous subgroups. No significant interactions were 
seen between the CABG procedure and any of the 
subgroup variables, with the exception of diabe-
tes status (Fig. 2, and Table S5 in the Supplemen-
tary Appendix). At 4.8 years after randomization, 
among patients with diabetes, the second copri-
mary outcome had occurred in 250 patients 
(22.7%) in the off-pump group and in 294 pa-
tients (26.1%) in the on-pump group (hazard 
ratio, 0.85; 95% CI, 0.72 to 1.01; P = 0.06). 
Among the patients who did not have diabetes, 
the second coprimary outcome occurred in 298 
patients (23.4%) in the off-pump group and in 
266 patients (21.3%) in the on-pump group (haz-
ard ratio, 1.12; 95% CI, 0.95 to 1.32; P = 0.19) 
(P = 0.02 for the interaction [not corrected for 
multiple testing]).
Discussion
In CORONARY, we compared off-pump CABG 
with on-pump CABG in 4752 participants from 
19 countries on four continents. At a mean of 
4.8 years of follow-up, we found no significant 
Type of Cost Off-Pump Group On-Pump Group
Between-Group 
Difference
mean cost in U.S. dollars*
Initial hospitalization
Total cost (95% CI) 9,959 
(9,925 to 10,612)
9,914 
(9,581 to 10,329)
45 
(−596 to 685)
Cost of procedures 1,978 1,934 44
Cost of ICU stay 5,000 5,060 −60
Cost of ward stay 2,981 2,920 61
Discharge to year 1 follow‑up
Total cost (95% CI) 1,322 
(1,153 to 1,554)
1,206 
(1,067 to 1,398)
115 
(−143 to 374)
Cost of procedures 110 81 29
Cost of events 482 417 65
Cost of medication 730 708 22
Year 1 follow‑up to end of trial
Total cost (95% CI) 3,826 
(3,563 to 4,151)
3,871 
(3,591 to 4,198)
−45 
(−463 to 373)
Cost of procedures 209 252 −43
Cost of events 886 937 −51
Cost of medication 2,731 2,682 49
Total cost (95% CI) 15,107 
(14,554 to 15,844)
14,992 
(14,504 to 15,530)
115 
(−697 to 927)
Total discounted cost (95% CI) 13,286 
(12,805 to 13,897)
13,190 
(12,764 to 13,660)
96 
(−607 to 799)
*  Costs are in U.S. currency for the year 2016.
Table 2. Mean Costs per Patient.
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difference between the groups in the second 
coprimary outcome of death, nonfatal stroke, 
nonfatal myocardial infarction, nonfatal new re-
nal failure requiring dialysis, or repeat revascular-
ization (PCI or CABG) and no significant differ-
ence in any component of the second coprimary 
outcome. In addition, we found no significant 
differences between the two techniques with re-
gard to rates of recurrent angina, repeat angiog-
raphy, repeat revascularization (PCI or CABG), 
or cardiovascular death, as well as no significant 
differences in cost or quality of life.
Investigators from three small trials18-20 involv-
ing a total of 768 patients with 5 years of follow-
up data have also published their long-term re-
sults, and they found no significant differences 
between the two techniques. However, some 
nonrandomized trials have reported lower rates 
of long-term survival21,22 in association with off-
pump CABG, as well as higher rates of repeat 
revascularization.23,24 On the basis of these re-
sults, some authors25,26 have recommended that 
off-pump CABG be abandoned. Although at 30 
days in CORONARY, fewer grafts had been per-
formed in the off-pump group, and the off-pump 
group had had a higher rate of crossover to the 
other procedure (relative risk, 1.23; 95% CI, 1.00 
to 1.50; P = 0.06) and a higher rate of incomplete 
revascularization (relative risk, 1.18; 95% CI, 1.0 to 
1.39; P = 0.05),12 at 5 years there was no signifi-
cant difference in any outcome between the two 
techniques, even among patients who crossed 
over to the other procedure or received an incom-
plete revascularization during their CABG proce-
dure (Table S6 in the Supplementary Appendix).
We found an apparent differential effect of the 
two approaches to surgery according to whether 
patients had diabetes. Although diabetes status 
was a prespecified subgroup variable at the in-
ception of the trial, we did not specify a reason 
to expect a difference between the treatment 
groups. Our intention was to examine the con-
Measure Off-Pump Group On-Pump Group P Value
No. of 
Patients Score
No. of 
Patients Score
EQ-5D†
Baseline 1424 0.77±0.22 1421 0.77±0.22 0.97
Change from baseline
To discharge 1265 −0.03±0.28 1251 −0.03±0.26 0.75
To 30 days 1154 0.07±0.26 1161 0.08±0.25 0.25
To 1 yr 1045 0.13±0.25 1055 0.15±0.24 0.26
To end of trial 1059 0.12±0.25 1071 0.13±0.26 0.28
EQ-5D visual-analogue scale‡
Baseline 1423 65.8±17.6 1422 66.6±17.8 0.24
Change from baseline
To discharge 1264 1.8±18.2 1250 1.0±17.8 0.27
To 30 days 1154 8.5±17.6 1159 8.0±17.6 0.44
To 1 year 1044 11.3±17.9 1055 11.5±17.6 0.86
To end of trial 1055 10.4±20.4 1069 10.4±20.9 0.99
*  Plus–minus values are means ±SD. The number of patients at baseline is the number of patients who performed the 
baseline test. The number of patients at each subsequent time is the number of patients who performed the test both 
at baseline and at that specific time.
†  The European Quality of Life–5 Dimensions questionnaire (EQ‑5D) assesses five dimensions of quality of life. The total 
score ranges from 0 to 1, with higher scores indicating better quality‑of‑life status.
‡  The EQ‑5D visual‑analogue scale assesses the respondent’s self‑rated health on a vertical visual‑analogue scale. The 
 total score ranges from 0 to 100%, with higher scores indicating better status.
Table 3. Quality-of-Life Results.*
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sistency of effects of the two types of CABG and 
was motivated by the results of trials of CABG 
(mostly on-pump) versus PCI in which CABG 
was found to be superior to PCI, particularly 
among patients with diabetes.27,28 Our results 
suggesting that there may be an interaction be-
tween CABG type and diabetes status should be 
viewed in light of the fact that we did examine 
several other prespecified subgroups and that so 
far none of the other trials have reported a sig-
Figure 2. Hazard Ratios for the Second Coprimary Outcome in Prespecified Subgroups.
Grades of 0 to 2 on the European System for Cardiac Operative Risk Evaluation (EuroSCORE) for CABG indicate low risk; 3 to 5, moder‑
ate risk; and more than 5, high risk. The body‑mass index is the weight in kilograms divided by the square of the height in meters.
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nificant interaction with this variable. Our re-
sults should stimulate a systematic analysis of 
data from all other trials on the relative long-
term effect of the two techniques according to 
diabetes status. Therefore, until further confir-
mation is available from other trials, caution 
should be exercised in interpreting this subgroup 
result.
It is not surprising that the results of our cost 
analysis reflect the results of the primary analy-
sis, with no significant differences between the 
treatment groups: off-pump CABG cost only $96 
more than on-pump CABG (discounted), a differ-
ence that is neither statistically nor financially 
significant. Therefore, we did not perform a stan-
dard cost-effectiveness analysis. One important 
limitation of our cost analysis is the fact that the 
specific costs of CABG supplies (off-pump retrac-
tors or cardiopulmonary bypass circuits) were 
not included. Hospitals keep the costs of CABG 
supplies confidential, and we were not able to 
obtain those data. The costs of CABG supplies 
for each technique are generally made similar 
within each hospital by various vendors. Although 
cardiopulmonary bypass circuits are not reusable, 
some reusable off-pump retractors are available 
on the market, and the use of these retractors 
for off-pump CABG rather than the nonreusable 
cardiopulmonary bypass circuits for on-pump 
CABG could generate important savings.
The quality-of-life and neurocognitive tests 
were optional. We were unable to provide an as-
sessment of neurocognitive status at the end of 
the trial. We made a decision to forgo the pre-
planned neurocognitive testing at the final fol-
low-up for three reasons: we had encountered 
substantial difficulties in obtaining 1-year neuro-
cognitive testing data (e.g., among the three 
tests evaluated, the highest completion rate was 
61% at 1 year),13 we recognized that obtaining 
face-to-face follow-up data for neurocognitive test-
ing at 5 years was likely to be even more difficult 
than at 1 year, and we had limited resources. 
Participation in the quality-of-life assessment was 
better, but some patients who chose not to par-
ticipate initially or who declined to participate 
later during the follow-up period might have 
differed in some ways from those who did par-
ticipate. Various sensitivity analyses suggested 
that the results were robust and indicated little 
difference, if any, in quality of life between the 
patients in the two groups. It is a testimony to 
CABG surgery that the increase in the quality 
of life observed after surgery was maintained to 
the end of the trial.
Our trial has some limitations, as described 
previously.12,13 However, our trial emphasizes the 
importance of long-term follow-up in surgical 
trials and indicates that new surgical techniques 
should be subject to rigorous comparative and 
large randomized trials before they are adopted 
widely in practice.
In conclusion, we conducted a large, random-
ized trial to compare the outcomes of on-pump 
CABG with those of off-pump CABG. At 5 years, 
we found no significant difference between the 
two groups in the rate of death, nonfatal stroke, 
nonfatal myocardial infarction, or nonfatal new 
renal failure requiring dialysis or in the rate of 
subsequent revascularization procedures. We also 
found no significant difference in cost or quality 
of life between the two techniques. Our trial 
results indicate that both procedures are equally 
effective and safe.
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